Brian J. Wentworth
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Brian J. Wentworth has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
- Helmy M. Siragy
Department of Medicine, Division of Endocrinology and Metabolism University of Virginia Charlottesville Virginia USA
4 shared publications - Mary McGrath
Department of Medicine University of Virginia School of Medicine Charlottesville Virginia USA
3 shared publications - Matthew Schliep
Department of Medicine, School of Medicine University of Virginia Charlottesville Virginia USA
3 shared publications Zachary H. Henry
Division of Gastroenterology and Hepatology
3 shared publications- Zachary H. Henry
Division of Gastroenterology & Hepatology, School of Medicine, University of Virginia, Charlottesville, USA
3 shared publications - Calvin X. Geng
Department of Medicine, University of Virginia, Charlottesville, Virginia
2 shared publications
Latest Publications
- Open Access
- 16 July 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 85 (6) , 1107-1117
Impact of non-selective beta-blockers on acute kidney injury outcomes in patients with decompensated cirrhosis
- 16 July 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 85 (6) , 1107-1117
Open AccessImpact of non-selective beta-blockers on acute kidney injury outcomes in patients with decompensated cirrhosis
- Open Access
Dosing and Route of Steroid Induction Therapy in Non‐Severe Autoimmune Hepatitis Do Not Affect Time to Biochemical Response
Background and Aims: Optimal steroid induction therapy in autoimmune hepatitis (AIH) is unclear. We aimed to investigate the relationship between steroid dosing, route of administration, and time to biochemical response to help standardize AIH practice patterns and reduce excess steroid exposure. Methods: We conducted a retrospective cohort study of adult patients with non‐severe AIH receiving induction steroid therapy. Patients were stratified into three treatment groups: (1) low‐dose oral steroids ( n = 39; prednisone < 40 mg/day or budesonide 9 mg/day), (2) high‐dose oral steroids ( n = 32; prednisone 40 mg/day), and (3) intravenous steroids ( n = 21; methylprednisolone 1 g/day). Time to biochemical response and predictors of biochemical response were compared at 6‐ and 12‐month intervals. Results: Rates of biochemical response were similar between the low‐ and high‐dose oral steroid groups at 6 months (72% vs. 78%, p = 0.54) and 12 months (92% vs. 91%, p = 1.00). Regarding high‐dose oral versus IV steroid induction, rates of biochemical response were similar between groups at 6 months (78% vs. 86%, p = 0.72) and 12 months (91% vs. 90%, p = 1.00). Time to biochemical response was not significantly different across all groups at both 6 and 12 months (log‐rank test, p = 0.23 and p = 0.42, respectively). Initial biomarkers of disease severity were not predictive of time to biochemical response across groups. Conclusions: Lower dose prednisone may be an effective initial induction regimen in outpatients with AIH. Similarly, oral steroids may be non‐inferior to IV steroids. Together, these results favor a more conservative approach for non‐severe AIH induction therapy.
Open AccessDosing and Route of Steroid Induction Therapy in Non‐Severe Autoimmune Hepatitis Do Not Affect Time to Biochemical Response
Background and Aims: Optimal steroid induction therapy in autoimmune hepatitis (AIH) is unclear. We aimed to investigate the relationship between steroid dosing, route of administration, and time to biochemical response to help standardize AIH practice patterns and reduce excess steroid exposure. Methods: We conducted a retrospective cohort study of adult patients with non‐severe AIH receiving induction steroid therapy. Patients were stratified into three treatment groups: (1) low‐dose oral steroids ( n = 39; prednisone < 40 mg/day or budesonide 9 mg/day), (2) high‐dose oral steroids ( n = 32; prednisone 40 mg/day), and (3) intravenous steroids ( n = 21; methylprednisolone 1 g/day). Time to biochemical response and predictors of biochemical response were compared at 6‐ and 12‐month intervals. Results: Rates of biochemical response were similar between the low‐ and high‐dose oral steroid groups at 6 months (72% vs. 78%, p = 0.54) and 12 months (92% vs. 91%, p = 1.00). Regarding high‐dose oral versus IV steroid induction, rates of biochemical response were similar between groups at 6 months (78% vs. 86%, p = 0.72) and 12 months (91% vs. 90%, p = 1.00). Time to biochemical response was not significantly different across all groups at both 6 and 12 months (log‐rank test, p = 0.23 and p = 0.42, respectively). Initial biomarkers of disease severity were not predictive of time to biochemical response across groups. Conclusions: Lower dose prednisone may be an effective initial induction regimen in outpatients with AIH. Similarly, oral steroids may be non‐inferior to IV steroids. Together, these results favor a more conservative approach for non‐severe AIH induction therapy.
- Open Access
Performance of Early Therapeutic Paracentesis in Spontaneous Bacterial Peritonitis and Its Effect on Clinical Outcomes
Background and Aims: Spontaneous bacterial peritonitis (SBP) is common in decompensated cirrhosis and often accompanied by large volume ascites. However, the safety of early therapeutic paracentesis is unknown and may lead to unnecessary delay in procedural performance. We aimed to assess whether paracentesis performance characteristics in the setting of SBP influenced renal or circulatory outcomes. Methods: A single‐center, retrospective cohort study was performed involving adult patients diagnosed with SBP based on ascites fluid studies during index admission between 2010 and 2020. Patient and procedural characteristics were collected and analyzed with respect to paracentesis timing (early vs. delayed) and volume (diagnostic only vs. non‐large volume therapeutic vs. large volume therapeutic). The primary outcome was a composite of the development of AKI and/or circulatory dysfunction. Secondary outcomes included 30‐day mortality, 90‐day mortality, and change in baseline renal function. Results: One‐hundred forty‐four patients met inclusion criteria during the study timeframe (Child‐Pugh C 74%, mean MELD‐Na 25). Sixty‐six (46%) met ACLF criteria at the time of SBP diagnosis. One‐hundred eight (75%) patients underwent a therapeutic paracentesis, of which approximately two‐thirds were performed within 24 h of admission (early); 41% were large volume (≥ 5 L of ascites removed). There was no difference in rates of the primary outcome with respect to either paracentesis timing or volume. Short‐term mortality and change in baseline renal function were independent of procedural characteristics. Conclusions: Therapeutic paracentesis does not appear to induce renal or circulatory dysfunction in patients with SBP.
Open AccessPerformance of Early Therapeutic Paracentesis in Spontaneous Bacterial Peritonitis and Its Effect on Clinical Outcomes
Background and Aims: Spontaneous bacterial peritonitis (SBP) is common in decompensated cirrhosis and often accompanied by large volume ascites. However, the safety of early therapeutic paracentesis is unknown and may lead to unnecessary delay in procedural performance. We aimed to assess whether paracentesis performance characteristics in the setting of SBP influenced renal or circulatory outcomes. Methods: A single‐center, retrospective cohort study was performed involving adult patients diagnosed with SBP based on ascites fluid studies during index admission between 2010 and 2020. Patient and procedural characteristics were collected and analyzed with respect to paracentesis timing (early vs. delayed) and volume (diagnostic only vs. non‐large volume therapeutic vs. large volume therapeutic). The primary outcome was a composite of the development of AKI and/or circulatory dysfunction. Secondary outcomes included 30‐day mortality, 90‐day mortality, and change in baseline renal function. Results: One‐hundred forty‐four patients met inclusion criteria during the study timeframe (Child‐Pugh C 74%, mean MELD‐Na 25). Sixty‐six (46%) met ACLF criteria at the time of SBP diagnosis. One‐hundred eight (75%) patients underwent a therapeutic paracentesis, of which approximately two‐thirds were performed within 24 h of admission (early); 41% were large volume (≥ 5 L of ascites removed). There was no difference in rates of the primary outcome with respect to either paracentesis timing or volume. Short‐term mortality and change in baseline renal function were independent of procedural characteristics. Conclusions: Therapeutic paracentesis does not appear to induce renal or circulatory dysfunction in patients with SBP.
- Open Access
- 31 December 2025
- Published by Kosin University College of Medicine in Kosin Medical Journal
- Vol. 40 (4) , 249-269
Autoimmune hepatitis: current concepts in epidemiology, diagnosis, and management
Autoimmune hepatitis is a rare immune-mediated liver disease that can progress to cirrhosis and liver failure. Its global incidence and prevalence are increasing, with a marked female predominance and substantial regional variation. Diagnosis requires the exclusion of alternative causes of liver disease and the integration of clinical, serologic, and histologic features. First-line induction therapy has traditionally relied on corticosteroids, with or without azathioprine, although recent evidence supports mycophenolate mofetil as an alternative first-line, steroid-sparing agent. Nonetheless, a subset of patients are intolerant of or have an inadequate response to first-line therapies, which complicates management and necessitates the use of less well-validated immunosuppressive regimens. Special clinical situations, including pregnancy, overlap syndromes, liver transplantation, and hepatocellular carcinoma, pose additional management challenges. For most patients, the primary therapeutic goal is complete biochemical response, although subclinical histologic inflammation may persist in some cases. Accordingly, careful long-term monitoring is essential to assess disease progression and to detect disease-specific or immunosuppression-related complications. This review concisely summarizes the current literature on autoimmune hepatitis and provides busy clinicians with a practical, evidence-based primer on disease management.
- 31 December 2025
- Published by Kosin University College of Medicine in Kosin Medical Journal
- Vol. 40 (4) , 249-269
Open AccessAutoimmune hepatitis: current concepts in epidemiology, diagnosis, and management
Autoimmune hepatitis is a rare immune-mediated liver disease that can progress to cirrhosis and liver failure. Its global incidence and prevalence are increasing, with a marked female predominance and substantial regional variation. Diagnosis requires the exclusion of alternative causes of liver disease and the integration of clinical, serologic, and histologic features. First-line induction therapy has traditionally relied on corticosteroids, with or without azathioprine, although recent evidence supports mycophenolate mofetil as an alternative first-line, steroid-sparing agent. Nonetheless, a subset of patients are intolerant of or have an inadequate response to first-line therapies, which complicates management and necessitates the use of less well-validated immunosuppressive regimens. Special clinical situations, including pregnancy, overlap syndromes, liver transplantation, and hepatocellular carcinoma, pose additional management challenges. For most patients, the primary therapeutic goal is complete biochemical response, although subclinical histologic inflammation may persist in some cases. Accordingly, careful long-term monitoring is essential to assess disease progression and to detect disease-specific or immunosuppression-related complications. This review concisely summarizes the current literature on autoimmune hepatitis and provides busy clinicians with a practical, evidence-based primer on disease management.
- 30 August 2025
- Published by Wiley in Clinical Transplantation
- Vol. 39 (9) , e70298
Adrenal Dysfunction in Cirrhosis Does Not Affect Liver Transplantation‐Related Outcomes
- 30 August 2025
- Published by Wiley in Clinical Transplantation
- Vol. 39 (9) , e70298
Adrenal Dysfunction in Cirrhosis Does Not Affect Liver Transplantation‐Related Outcomes
- Open Access
- 26 July 2025
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 70 (12) , 4247-4258
Adrenal Dysfunction in Outpatients with Decompensated Cirrhosis: Impairment in the Hypothalamic–Pituitary–Adrenal Axis
Background and Aims The pathogenesis of adrenal dysfunction (AD) in cirrhosis is incompletely understood. We aimed to evaluate potential effects of cirrhosis on hypothalamic–pituitary–adrenal axis (HPA) functionality in stable outpatients with decompensated disease. Methods Outpatients with decompensated cirrhosis were prospectively recruited at a transplant center. Biomarkers reflective of HPA activity, glucocorticoid synthesis, cholesterol metabolism, systemic neurohormonal activity, and the immune system were measured prior to administration of a standard-dose adrenocorticotrophic hormone (ACTH) stimulation test. Adrenal dysfunction was defined as an increase in serum total cortisol level (delta TC) of < 9 µg/dL. Patients were followed for up to 12 months for assessment of clinical outcomes including portal hypertension-related decompensation, hospitalization, liver transplant, and death. Results Seventy-six participants were enrolled (AD 33%, normal adrenal function 67%). Median ACTH levels were similar between groups (P = 0.581). The product ratio of the cortisol precursor 17-hydroxyprogesterone to 11-deoxycortisol (11-DOC) was lower in the AD group (0.9 vs. 1.3, P = 0.036), whereas the 11-DOC:cortisol ratio was similar between groups (5.9 vs. 5.0, P = 0.522). Of the 13 measured serum cytokines, only median levels of IL-6 were significantly higher in the AD group (14.71 vs. 8.99 pg/mL, P = 0.024). There were no differences in clinical outcomes between groups. Conclusions Inappropriately low ACTH secretion and alterations in adrenal steroidogenesis are associated with an abnormal response to ACTH stimulation testing in outpatients with decompensated cirrhosis. These findings suggest multilevel HPA axis dysfunction and support the theory that AD represents cirrhosis-induced extrahepatic organ failure. The presence of AD may not be associated with worse liver-related outcomes.
- 26 July 2025
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 70 (12) , 4247-4258
Open AccessAdrenal Dysfunction in Outpatients with Decompensated Cirrhosis: Impairment in the Hypothalamic–Pituitary–Adrenal Axis
Background and Aims The pathogenesis of adrenal dysfunction (AD) in cirrhosis is incompletely understood. We aimed to evaluate potential effects of cirrhosis on hypothalamic–pituitary–adrenal axis (HPA) functionality in stable outpatients with decompensated disease. Methods Outpatients with decompensated cirrhosis were prospectively recruited at a transplant center. Biomarkers reflective of HPA activity, glucocorticoid synthesis, cholesterol metabolism, systemic neurohormonal activity, and the immune system were measured prior to administration of a standard-dose adrenocorticotrophic hormone (ACTH) stimulation test. Adrenal dysfunction was defined as an increase in serum total cortisol level (delta TC) of < 9 µg/dL. Patients were followed for up to 12 months for assessment of clinical outcomes including portal hypertension-related decompensation, hospitalization, liver transplant, and death. Results Seventy-six participants were enrolled (AD 33%, normal adrenal function 67%). Median ACTH levels were similar between groups (P = 0.581). The product ratio of the cortisol precursor 17-hydroxyprogesterone to 11-deoxycortisol (11-DOC) was lower in the AD group (0.9 vs. 1.3, P = 0.036), whereas the 11-DOC:cortisol ratio was similar between groups (5.9 vs. 5.0, P = 0.522). Of the 13 measured serum cytokines, only median levels of IL-6 were significantly higher in the AD group (14.71 vs. 8.99 pg/mL, P = 0.024). There were no differences in clinical outcomes between groups. Conclusions Inappropriately low ACTH secretion and alterations in adrenal steroidogenesis are associated with an abnormal response to ACTH stimulation testing in outpatients with decompensated cirrhosis. These findings suggest multilevel HPA axis dysfunction and support the theory that AD represents cirrhosis-induced extrahepatic organ failure. The presence of AD may not be associated with worse liver-related outcomes.
- 29 May 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (12) , 2746-2749
Primary Biliary Cholangitis in 2025: A New Frontier
An abstract is unavailable. This article is available as a PDF only.
- 29 May 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (12) , 2746-2749
Primary Biliary Cholangitis in 2025: A New Frontier
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 1 January 2025
- Published by Wiley in Canadian Journal of Gastroenterology and Hepatology
- Vol. 2025 (1) , 8894058
Association Between Older Age and TIPS‐Related Hospitalization Following Shunt Placement
Background and Aims: Patients experience more complications of portal hypertension as liver disease progresses, many of which can be managed by transjugular intrahepatic portosystemic shunt (TIPS) insertion. Controversy surrounds the association of age with TIPS‐related complications. We sought to evaluate the effect of age on TIPS‐associated outcomes, including hospital admissions. Methods: This retrospective, bicentric cohort study included patients who underwent TIPS insertion between January 1, 2006, and December 31, 2016. The primary outcome of the study was predictors of liver‐related hospital admission within 12 months of TIPS insertion between patients < 70 years and ≥ 70 years old. Secondary outcomes included mortality at 12 months and MELD‐Na score at 90 days following TIPS placement. Results: A total of 593 patients were included in the study—487 patients were less than 70 years old while 106 patients were 70 years of age or older. Near equal percentages of elderly and nonelderly patients were admitted with post‐TIPS complications within 12 months of insertion (29.2% v. 29.0%, p = 0.91). Pre‐existing diagnoses of diabetes and/or hypertension, hepatic hydrothorax, as well as serum creatinine and/or serum sodium at the time of TIPS insertion were associated with TIPS‐related admissions within the first 12 months of shunt insertion. Conclusion: TIPS placement in selected older patients can be safe. Age should not be a strict contraindication for TIPS insertion, but discussion regarding risks and benefits of the procedure should be individualized.
- 1 January 2025
- Published by Wiley in Canadian Journal of Gastroenterology and Hepatology
- Vol. 2025 (1) , 8894058
Open AccessAssociation Between Older Age and TIPS‐Related Hospitalization Following Shunt Placement
Background and Aims: Patients experience more complications of portal hypertension as liver disease progresses, many of which can be managed by transjugular intrahepatic portosystemic shunt (TIPS) insertion. Controversy surrounds the association of age with TIPS‐related complications. We sought to evaluate the effect of age on TIPS‐associated outcomes, including hospital admissions. Methods: This retrospective, bicentric cohort study included patients who underwent TIPS insertion between January 1, 2006, and December 31, 2016. The primary outcome of the study was predictors of liver‐related hospital admission within 12 months of TIPS insertion between patients < 70 years and ≥ 70 years old. Secondary outcomes included mortality at 12 months and MELD‐Na score at 90 days following TIPS placement. Results: A total of 593 patients were included in the study—487 patients were less than 70 years old while 106 patients were 70 years of age or older. Near equal percentages of elderly and nonelderly patients were admitted with post‐TIPS complications within 12 months of insertion (29.2% v. 29.0%, p = 0.91). Pre‐existing diagnoses of diabetes and/or hypertension, hepatic hydrothorax, as well as serum creatinine and/or serum sodium at the time of TIPS insertion were associated with TIPS‐related admissions within the first 12 months of shunt insertion. Conclusion: TIPS placement in selected older patients can be safe. Age should not be a strict contraindication for TIPS insertion, but discussion regarding risks and benefits of the procedure should be individualized.
- Open Access
- 26 December 2024
- Published by OAE Publishing Inc. in Metabolism and Target Organ Damage
- Vol. 4 (4)
Metabolic dysfunction-associated steatotic liver disease throughout the liver transplant cycle: a comprehensive review
Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing in global prevalence and becoming a leading indication for liver transplantation (LT). The management of MASLD has been well-studied in the pre-LT setting, and we are entering into a golden era of pharmacologic options designed to resolve steatohepatitis and reverse fibrosis. However, the implications of MASLD on organ allocation, risk of post-LT recurrence, and optimal post-LT management remain topics of ongoing investigation. One such unique challenge is the growing necessity to use steatotic organs to address the shortage of available organs for all waitlisted patients, while ensuring acceptable outcomes through careful case selection. Additionally, how best to screen, diagnose, and manage post-LT graft steatosis remains an ongoing topic of debate, given the high rates of recurrence or de novo occurrence in patients transplanted for non-MASLD-related etiologies of liver disease. This comprehensive review explores the impact of MASLD across the disease continuum, given it is a chronic illness with a complex pathophysiology and is influenced by other comorbidities and certain medications.
- 26 December 2024
- Published by OAE Publishing Inc. in Metabolism and Target Organ Damage
- Vol. 4 (4)
Open AccessMetabolic dysfunction-associated steatotic liver disease throughout the liver transplant cycle: a comprehensive review
Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing in global prevalence and becoming a leading indication for liver transplantation (LT). The management of MASLD has been well-studied in the pre-LT setting, and we are entering into a golden era of pharmacologic options designed to resolve steatohepatitis and reverse fibrosis. However, the implications of MASLD on organ allocation, risk of post-LT recurrence, and optimal post-LT management remain topics of ongoing investigation. One such unique challenge is the growing necessity to use steatotic organs to address the shortage of available organs for all waitlisted patients, while ensuring acceptable outcomes through careful case selection. Additionally, how best to screen, diagnose, and manage post-LT graft steatosis remains an ongoing topic of debate, given the high rates of recurrence or de novo occurrence in patients transplanted for non-MASLD-related etiologies of liver disease. This comprehensive review explores the impact of MASLD across the disease continuum, given it is a chronic illness with a complex pathophysiology and is influenced by other comorbidities and certain medications.
- 25 October 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (1) , 9-15
Autoimmune Hepatitis and the Pathways and Targets for Therapies
An abstract is unavailable. This article is available as a PDF only.
- 25 October 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (1) , 9-15
Autoimmune Hepatitis and the Pathways and Targets for Therapies
An abstract is unavailable. This article is available as a PDF only.